GlassScriptPhysician profile
Carly Esposito
NPI 1871170472
$2,828.56
in general payments reported to CMS, 2019-2025
20 companies · $2,072 in 2025
The $2,072 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8.32 · 2022: $18.59 · 2023: $247 · 2024: $482 · 2025: $2,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $649.59 | 2023-2025 | |
| Amgen INC. | $320.66 | 2024-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $313.07 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $275.80 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $178.29 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $175.21 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $164.30 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $130.57 | 2024-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $116.19 | 2024-2025 | Heplisav-B |
| Lilly USA, LLC | $104.26 | 2024-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $75.30 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.11 | 2024-2025 | |
| Pfizer INC. | $60.19 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.74 | 2025 | Xifaxan |
| Shield Therapeutics INC | $44.37 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.37 | 2025 | Freestyle Libre 3 |
| Krystal Biotech INC | $24.16 | 2025 | Vyjuvek |
| Janssen Pharmaceuticals, INC | $22.57 | 2024 | Xarelto |
| Microtransponder, INC. | $19.49 | 2025 | |
| Organon LLC | $8.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Esposito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.